anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Immunoglobulin A vasculitis, historically known as Henoch-Schönlein purpura, is a rare form of autoimmune-induced vasculitis most common in children. This disease is characterized by a purpuric rash, arthritis, digestive tract complication, and renal inflammation (Hopkins).
CASE REPORT: We present the case of a 78-year-old man in the emergency department with findings of weakness, abdominal pain, and bloody diarrhea for 3 days and a new-onset bilateral lower extremity rash. Diagnostic imaging and labs diagnosed this patient with immunoglobulin A vasculitis (IgAV) with associated acute kidney injury and abdominal mesenteric edema. Why Should an Emergency Physician be Aware of This? Recognition of IgAV by emergency physicians and assessment of multiple organ involvement is critical to expedite treatment and minimize complications. Particularly, physicians should consider and recognize the increased severity and different presentation of IgAV in adults in comparison with the more widely known manifestation in children.
BACKGROUND: Neuropathic pain (NP) is a challenging health condition owing to its complex nature and associated multiple etiologies. The occurrence of NP involves the abnormal activity of neurons mediated by oxidative stress (OS). Previous research has demonstrated that m6A methylation plays a role in the regulatory pathway of NP. This study aimed to investigate the specific molecular pathways through which m6A methylation modifiers alleviate NP.
METHODS: For this purpose, an NO rat model was developed via spared nerve injury (SNI), followed by quantifying the animal's pain assessment via paw withdrawal threshold (PWT) and paw withdrawal latency (PWL). The OS in SNI rats was evaluated by measuring reactive oxygen species, superoxide dismutase, and catalase (CAT) in spinal cord tissues. Moreover, quantitative-real-time polymerase chain reaction and western blot analysis were employed for detecting fat mass and obesity-associated (FTO) and GPR177 levels, while m6A levels of GPR117 were analyzed via MeRIP.
RESULTS: The results indicated an enhanced OS with highly expressed FTO in spinal cord tissue samples, where knocking down Fto effectively relieved NP and OS in SNI rats. Mechanistic investigations revealed that Fto-mediated reduction of Grp177 m6A modification was involved in the WNT5a/TRPV1 axis-mediated OS remission of NP. Moreover, in vitro experiment results indicated that YTHDF2 was an important m6A methylated reading protein for this process.
CONCLUSIONS: Fto silencing leads to increased m6A methylation of Grp177 through a YTHDF2-dependent mechanism, resulting in decreased Grp177 stability and ultimately reducing NP in rats by OS suppression.
The invention relates to a curing and healing ointment used for curing the damage of big muscle, muscle fracture, pyogenic infection, carbuncle and surgery cut, in particular to a granulation-promoting ointment which can ensures the quick growth of fester soft tissues without leaving remarkable sclerosis and scars. The ointment consists of xanthium worm (1), rust powder (2), vermilion (3), scorpion (4), calcined alum (5) (dewatered alum) and beeswax (6). The curing and healing ointment has the main functions of detumescence and toxin drawing-out as well as pus drainage and removal of necrotic tissue. The invention relates to a preparation method of the granulation-promoting ointment which consists of 20 fresh xanthium worms (1), 2.4g of the rust powder (2), 2.4g of the vermilion (3), 3g of the scorpion (4), 6g of the calcined alum (5) (dewatered alum) and 20g of the beeswax (6). In the method, the xanthium worms are dipped in benne oil for 7 days and the scorpion is fried. The rust powder, the scorpion powder, the calcined alum, the beeswax and the vermilion are heated and mixed uniformly, cooled and then the xanthium worms and proper amount of the benne oil are added and mashed into ointment for standby. The curing and healing ointment has the main functions of detumescence and toxin drawing-out as well as pus drainage and removal of necrotic tissue, and has stronger sterilization and infection-resistance capacities. The invention also has the advantages of easily obtained materials, novel and specific prescription, simple extraction technique and convenient medication.
Mycobacterium avium complex (MAC) is a serious disease that is mainly caused by infection with the non-tuberculous mycobacteria (NTM), Mycobacterium avium and Mycobacterium intracellulare. Seven new compounds, designated mavintramycins A-G (1-7), were isolated along with structurally related compounds, including amicetin (9) and plicacetin (10), from the culture broth of Streptomyces sp. OPMA40551 as anti-MAC compounds that were active against M. avium and M. intracellulare. Among them, mavintramycin A showed the most potent and selective inhibition of M. avium and M. intracellulare. Furthermore, mavintramycin A was active against more than 40 clinically isolated M. avium, including multidrug-resistant strains, and inhibited the growth of M. avium in a persistent infection cell model using THP-1 macrophages. Mavintramycin A also exhibited in vivo efficacy in silkworm and mouse infection assays with NTM. An experiment to elucidate its mechanism of action revealed that mavintramycin A inhibits protein synthesis by binding to 23S ribosomal RNA in NTM. Mavintramycin A, with a different chemical structure from those of clinically used agents, is a promising drug candidate for the treatment of MAC infectious disease.
This was a single arm open-label study. All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.
In rheumatoid arthritis, juvenile idiopathic arthritis and other forms of inflammatory arthritis, the immune system targets certain joints but not others. The pattern of joints affected varies by disease and by individual, with flares most commonly involving joints that were previously inflamed. This phenomenon, termed joint-specific memory, is difficult to explain by systemic immunity alone. Mechanisms of joint-specific memory include the involvement of synovial resident memory T cells that remain in the joint during remission and initiate localized disease recurrence. In addition, arthritis-induced durable changes in synovial fibroblasts and macrophages can amplify inflammation in a site-specific manner. Together with ongoing systemic processes that promote extension of arthritis to new joints, these local factors set the stage for a stepwise progression in disease severity, a paradigm for arthritis chronicity that we term the joint accumulation model. Although durable drug-free remission through early treatment remains elusive for most forms of arthritis, the joint accumulation paradigm defines new therapeutic targets, emphasizes the importance of sustained treatment to prevent disease extension to new joints, and identifies a rolling window of opportunity for altering the natural history of arthritis that extends well beyond the initiation phase of disease.
Compositions, systems, and methods that can be used with a pressurized metered dose inhaler are disclosed. A pharmaceutical composition for use in a pressurized metered dose inhaler can comprise a cannabinoid composition, a co-solvent, a terpene composition, and a propellant. A pharmaceutical composition may be soluble. A system can comprise a plurality of cannabinoid compositions and/or a plurality of terpene compositions available in various combinations. One of a plurality of cannabinoid compositions and terpene composition combinations may be user-selectable in response to various factors such as a desired therapeutic benefit, sedative effect, flavor profile, or a combination of the foregoing. A method of formulating a soluble pMDI pharmaceutical composition comprising a cannabinoid composition, a co-solvent, a terpene composition, and a propellant is disclosed.
FIELD: medicine, medicinal rehabilitation, lymphology. SUBSTANCE: one should carry out surface stroking at reciprocation of fingers by not shifting skin into folds. Then one should by palpation detect regional lymphatic nodes to affect them either separately or the whole conglomerate of lymph nodes with 5-6-fold pressure at their capturing together with skin fold at gradual power increase and pressing duration from 5-10 till 30-45 sec. Then one should carry out lymphodraining massage in areas and along projection of lymphatic collectors. Lymphodrainage is conducted either daily or in a day at 14 seances at the background of lymphotropic remedies intake. Additionally, at the beginning and/or at the end of lymphatic drainage seance it is necessary to perform lymphodrainage by using respiratory exercises. The method enables to increase drainage-detoxication function of lymphatic system, carry out sanitation of pericellular body medium. EFFECT: higher efficiency. 5 cl, 1 ex, 1 tbl
A nutraceutical composition including an extract from a fruit of  Garcinia mangostana L.  and a predetermined concentration of hydroxycitric acid. The concentration of the extract from the fruit of  Garcinia mangostana L . is substantially between 1% and 99% by weight of the nutraceutical composition and the predetermined concentration of hydroxycitric acid is substantially between 1% and 99% by weight. The hydroxycitric acid can be provided by an extract from the fruit of Garcinia atroviridis or Garcmia cambogia, and/or other natural or synthetic sources. The extract from the fruit of  Garcinia 
 mangostana L.  can be obtained from a fruit portion that includes the aril part. The nutraceutical composition can be included in a food product or a beverage or a component of one of a food product or a beverage. When consumed, the nutraceutical composition aids weight loss or weight control. In addition, when consumed, the nutraceutical composition stimulates the immune system, for instance, by inducing increased production of lnterleukin-2.
The 18-kDa isoform of basic fibroblast growth factor (bFGF/FGF2) lacks a conventional signal peptide sequence and is exported by a novel membrane-associated transport pathway. Extracellular vesicles (EVs) are increasingly recognized as mediators of intercellular communication in the lung, and our prior work demonstrates that EVs carry cargo that contributes to hyperoxic lung injury and are biomarkers for bronchopulmonary dysplasia. We used primary human bronchial epithelial (HBE), pulmonary artery endothelial (HPAE), and fibroblast (HNF) cells to determine whether FGF2 was secreted in EVs. EVs were isolated by ultracentrifugation from HBE, HPAE, and HNF exposed to either normoxia or hyperoxia, followed by nanoparticle tracking analysis and electron microscopy. Hyperoxia exposure increased the total EV number. All three cell types released FGF2-18kDa both directly into the extracellular environment (secretome), as well as in EVs. HBE released more FGF2-18kDa in EVs during hyperoxia, and these were internalized and localized to both nuclei and cytoplasm of recipient cells. By co-immunoprecipitation, we identified potential binding partners of FGF2-18kDa in the nuclei, including histone 1.2 (H1.2) binding protein, that may mediate downstream effects that do not involve FGF2 binding to cell surface receptors. FGF2-18kDa interaction with H1.2 binding protein may indicate a mechanism by which FGF2 secreted in EVs modulates cellular processes. FGF2 was also found to increase angiogenesis by Matrigel assay. Further studies are necessary to determine the biological relevance of FGF2 in EVs as modulators of lung injury and disease.NEW & NOTEWORTHY We found that multiple lung cell types release basic fibroblast growth factor (FGF2)-18kDa both directly into the extracellular environment (secretome), as well as in extracellular vesicles (EVs). Bronchial epithelial cells released more FGF2-18kDa in EVs during hyperoxia, which could be internalized rapidly by recipient cells. We also identified potential binding partners of FGF2-18kDa in nuclei that may mediate downstream effects that do not involve FGF2 binding to cell surface receptors. We also confirmed a potential angiogenic role for FGF2-18kDa.
NEW MATERIAL:A compound shown by the formula I (R is electron attractive group such as acyl, alkoxycarbonyl, aminocarbonyl, cyano, nitro, etc.). EXAMPLE:1,2-Thiazolo-4-amino-5-acetylimidazole. USE:An insecticide. PREPARATION:A 2-cyanoiminothiazolidine derivative [e.g., 2-(N-cyano-imino)-3- acetylmethyl-thiazo lidine,etc.] shown by the formula II is subjected to ring closure in the presence of preferably a catalytic amount of a base (e.g., metal sodium etc.) in a solvent such as usually DMF, lower alcohol, etc. to give a compound shown by the formula I . When an alcohol is used as the solvent, an alkali metal alkoxide of alcohol is preferable as the base, and when DMF, etc. is used as the solvent, and an alkali metal hydride such as sodium hydride, potassium hydride, etc. as the base.
Unwanted upper inner thigh fat is a common aesthetic complaint from patients, and current treatment options include liposuction and cryolipolysis (CoolSculpting, Allergan, Irvine, CA). Deoxycholic acid (Kybella, Allergan, Irvine, CA) is an FDA-approved injectable for the treatment of excess submental fat. At this time, it is not known if deoxycholic acid may be a safe and effective treatment for upper inner thigh fat. The proposed clinical trial will evaluate the safety and efficacy of deoxycholic acid for reduction of upper inner thigh fat.

In this single-arm, open-label safety and efficacy study, 15 subjects with excess upper inner thigh fat will receive 1-4 treatment sessions of subcutaneously injected deoxycholic acid. Subjects will be followed for 12 weeks after last treatment. Adverse events will be monitored. Efficacy will be objectively measured by change in thigh circumference; change in upper inner thigh skin fold thickness; increase in "thigh gap;" and percent accuracy by three blinded physicians in correctly identifying baseline photographs, upon independent review of before-and-after clinical photographs of the treatment area. Patient satisfaction related to the study treatment will be assessed with a Subject Self-Rating Scale throughout the study, and with a Post-Treatment Satisfaction Questionnaire.
For the management of endometriosis, the recommended daily dose of SYNAREL is 400 µg. This is achieved by one spray (200 µg) into one nostril in the morning and one spray into the other nostril in the evening. Treatment should be started between days 2 and 4 of the menstrual cycle.

In an occasional patient, the 400 µg daily dose may not produce amenorrhea. For these patients with persistent regular menstruation after 2 months of treatment, the dose of SYNAREL may be increased to 800 µg daily. The 800 µg dose is administered as one spray into each nostril in the morning (a total of two sprays) and again in the evening.

The recommended duration of administration is six months. Retreatment cannot be recommended since safety data for retreatment are not available. If the symptoms of endometriosis recur after a course of therapy, and further treatment with SYNAREL is contemplated, it is recommended that bone density be assessed before retreatment begins to ensure that values are within normal limits.

There appeared to be no significant effect of rhinitis, i.e., nasal congestion, on the systemic bioavailability of SYNAREL; however, if the use of a nasal decongestant for rhinitis is necessary during treatment with SYNAREL, the decongestant should not be used until at least 2 hours following dosing with SYNAREL.

Sneezing during or immediately after dosing with SYNAREL should be avoided, if possible, since this may impair drug absorption.

At 400 µg/day, a bottle of SYNAREL provides a 30-day (about 60 sprays) supply. If the daily dose is increased, increase the supply to the patient to ensure uninterrupted treatment for the recommended duration of therapy.
Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
PURPOSE:To provide an indometacin-contg. adhesive tape excellent in percutaneous absorption and therapeutic effect and well suited to occlusive dressing for inflammatory diseases, by forming a press.-sensitive adhesive layer contg. indometacin and a penetration assistant on impermeable films. CONSTITUTION:Indometacin and penetration assistants (e.g., glycyrrhetic acid) are mixed with a soln. of binders such as acrylate/acrylic acid copolymers or acrylate/vinyl acetate copolymers. Said mixed soln. is applied onto inpermeable films (e.g., polyethylene films, polyvinyl chloride films, polyvinyliden chloride films) to yield the intended indometacin-contg. adhesive tape. The proper amt. of indometacin or penetration assistants to be contained is about 60-400mug/cm<2> or 5-100mug/cm<2>, respectively. Said tape is used by directly applying to inflamed skin.
1441061 Nucleic acids and synthetic polypeptides RICHTER GEDEON VEGYESZETI GYAR RT 8 March 1974 10550/74 Headings C3H and C3R [Also in Division A5] Antiviral complexes or compositions are prepared from one or more inducers evoking viral resistance and one or more activators potentiating the activity of such inducers. They are produced by contacting a non- antigenic substance able to induce in living cells the production of natural antiviral agents and/or possessing antiviral activity in itself in an aqueous medium with a synthetic polycationic polypeptide (activator) built up totally or partially from α-amino acid units of the general formula wherein A represents a group, B represents an alkylene group of 1 to 4 carbon atoms, R 1  and R 2  are, independently from each other, hydrogen atoms or alkyl groups of 1 to 4 carbon atoms, or R 1  and R 2  together with the adjacent nitrogen atom form a five or six membered heterocyclic ring, containing optionally a further hetero atom, R 3  is an alkyl group of 1 to 4 carbon atoms, R 4  is hydrogen or an alkyl group of 1 to 4 carbon atoms, n is an integer from 1 to 5, or, if A represents a group, n may be also 0, or an acid addition salt or quaternary ammonium derivative thereof. The non-antigenic substance may be poly I : C, poly A : U, poly (AU) or statolon (Nature 220 167 (1968)). The activator may be derivatives of polyglutamic acid, polyaspartic acid or poly-2-aminoadipic acid in which the free carboxyl groups are amidated with 2- dimethyl aminoethylamine or 2-diethylaminoethylamine, the iodide salt of a derivative of polyglutamic acid in which the free carboxyl groups are amidated with 2-trimethyl- or 2- methyldiethyl-ammonium ethyl groups, the chloride salt of a derivative of polyglutamic acid in which the free carboxyl groups are amidated with 2-(butyl-dimethylammonium) ethyl groups, polyglutamic acid derivatives in which the free carboxyl groups are amidated with (1) (73% dimethyl aminoethyl, 15% 2- hydroxyethyl and 8% 2-imidazolylethyl groups, or (2) 48% 2-dimethylaminoethyl and 48% 2-aminoethyl groups, respectively, and methosulphate salts of derivatives of polylysine or polyernithine of which the free amino groups are methylated. The many complexes/compositions exemplified are composed of activatorinducer pairs from the above-mentioned non- antigenic substances and polypeptide activators. Diluted in sterile physiological sodium chloride solution or other conventional liquid solutions (specified) they may be filled into ampoules and stored in the frozen state. Alternatively the freeze-dried complex or composition admixed with lactose and starch may be processed into pills. The examples demonstrate the viral resistance in mice provoked by the administration of the complexes or compositions of the invention. Tests involving the use of cultures of tissue cells and of embrionated eggs are also disclosed.
Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
The recognition of host genetic factors underlying susceptibility to hematopoietic malignancies has increased greatly over the last decade. Historically, germline predisposition was thought to primarily affect the young. However, emerging data indicate that hematopoietic malignancies that develop in people of all ages across the human lifespan can derive from germline predisposing conditions and are not exclusively observed in younger individuals. The age at which hematopoietic malignancies manifest appears to correlate with distinct underlying biological pathways. Progression from having a deleterious germline variant to being diagnosed with overt malignancy involves complex, multistep gene-environment interactions with key external triggers, such as infection and inflammatory stimuli, driving clonal progression. Understanding the mechanisms by which predisposed clones transform under specific pressures may reveal strategies to better treat and even prevent hematopoietic malignancies from occurring.Recent unbiased genome-wide sequencing studies of children and adults with hematopoietic malignancies have revealed novel genes in which disease-causing variants are of germline origin. This paradigm shift is spearheaded by findings in myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) as well as acute lymphoblastic leukemia, but it also encompasses other cancer types. Although not without challenges, the field of genetic cancer predisposition is advancing quickly, and a better understanding of the genetic basis of hematopoietic malignancies risk affects therapeutic decisions as well as genetic counseling and testing of at-risk family members.
FIELD: medicine. ^ SUBSTANCE: presented strain of human immunodeficiency virus HIV-1 Al. RU. 09 RU 2255 is deposited in the Collection of Microorganisms of Federal State Research Institution State Science Centre Vector of Federal Service for Supervision of Consumer Rights and Human Welfare, No. V-412. ^ EFFECT: strain can be used for developing and improving HIV diagnostic techniques, studying the efficacy of therapeutic and preventive chemotherapeutic and vaccine preparations, and for creating a national panel of HIV-1 strains. ^ 4 dwg, 3 ex